Bridge to Life Welcomes Brian Lenz as New CFO to Drive Growth and Innovation

Bridge to Life Welcomes Brian Lenz as Chief Financial Officer

Introduction

Bridge to Life Ltd., a prominent name in organ preservation solutions, has made a significant addition to its executive team by appointing Brian Lenz as Chief Financial Officer (CFO). With over 20 years of experience in finance and leadership roles within the life sciences sector, Lenz is expected to play a crucial role in steering the company's future growth, especially with the anticipated launch of their latest innovation, VitaSmart™.

Background of Brian Lenz

Lenz's professional journey is marked by a successful tenure in various senior financial leadership roles. Before joining Bridge to Life, he spent 12 years as CFO and General Manager at ADMA Biologics, where he was instrumental in overseeing financial operations and driving significant revenue increases. His career also includes senior roles at CorMedix and other biotechnology firms, where he managed finances and strategic development effectively.

Notably, Lenz has a strong track record of financing, raising over $1 billion in equity and debt through active participation in mergers, acquisitions, and licensing transactions. These achievements underscore his capacity to enhance a company’s market position and profitability.

CEO's Remarks

Don Webber, CEO of Bridge to Life, expressed enthusiasm about Lenz's appointment, stating, "We are very pleased to welcome Brian to the executive leadership team... His excitement about Bridge to Life's future prospects, particularly the expected future FDA clearance of VitaSmart™, has only grown stronger."

The shared vision and trust built over Lenz’s time on the board for the past two and a half years played a vital role in his selection as CFO. Webber believes that his ability to drive financial discipline and team performance will further strengthen the company’s mission of expanding access to viable donor organs globally.

Lenz’s Vision for Bridge to Life

Reflecting on his new role, Lenz stated his eagerness to contribute to Bridge to Life’s growth. Having partnered with the team as a board member, he is well-acquainted with the company’s passion and innovation. His excitement about the upcoming launch of the VitaSmart™ system, which is poised to change the landscape of organ preservation, is particularly noteworthy. He sees this as an opportunity to significantly enhance the company’s capability to deliver vital donor organs to those in need.

The Future of VitaSmart™

VitaSmart™ represents a significant advancement in the field of organ preservation technology. The product has already received CE marking and is available in various markets outside of the United States. Pending FDA clearance will allow it to enter the U.S. market, presenting an exciting opportunity for the company. Under Lenz's financial stewardship, Bridge to Life aims to scale its operations effectively to meet the increasing demand for organ preservation solutions.

Conclusion

The appointment of Brian Lenz as CFO is a strategic move for Bridge to Life Ltd. His extensive experience in the life sciences, combined with a proactive approach to financial leadership, positions him to lead the company's ambitious growth strategies. As the company navigates through critical phases of product launch and market expansion, Lenz’s expertise will undoubtedly be a vital asset in fulfilling Bridge to Life’s mission to enhance the availability of donor organs across the globe.